Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd. - Ordinary Shares (NQ:ENLV)

1.120 -0.080 (-6.67%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 196,647
Open 1.180
Bid (Size) 1.110 (20)
Ask (Size) 1.300 (20)
Prev. Close 1.200
Today's Range 1.110 - 1.230
52wk Range 0.8101 - 1.760
Shares Outstanding 18,306,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
From Enlivex Therapeutics Ltd
Via GlobeNewswire

Performance

YTD
-9.7%
-9.7%
1 Month
+19.7%
+19.7%
3 Month
+15.4%
+15.4%
6 Month
-2.6%
-2.6%
1 Year
-18.8%
-18.8%

More News

Read More
Enlivex Selected to Present at Israeli BioMed 2025 Conference
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Which stocks have an unusual volume on Tuesday?
Via Chartmill
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
From Enlivex Therapeutics Ltd
Via GlobeNewswire
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis
Via ACCESS Newswire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
Via ACCESSWIRE
Enlivex Adopts Bitcoin Treasury Reserve Strategy
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Via ACCESSWIRE
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV)
Via AB Newswire

Frequently Asked Questions

Is Enlivex Therapeutics Ltd. - Ordinary Shares publicly traded?
Yes, Enlivex Therapeutics Ltd. - Ordinary Shares is publicly traded.
What exchange does Enlivex Therapeutics Ltd. - Ordinary Shares trade on?
Enlivex Therapeutics Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Enlivex Therapeutics Ltd. - Ordinary Shares?
The ticker symbol for Enlivex Therapeutics Ltd. - Ordinary Shares is ENLV on the Nasdaq Stock Market
What is the current price of Enlivex Therapeutics Ltd. - Ordinary Shares?
The current price of Enlivex Therapeutics Ltd. - Ordinary Shares is 1.120
When was Enlivex Therapeutics Ltd. - Ordinary Shares last traded?
The last trade of Enlivex Therapeutics Ltd. - Ordinary Shares was at 06/30/25 03:59 PM ET
What is the market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares?
The market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares is 20.50M
How many shares of Enlivex Therapeutics Ltd. - Ordinary Shares are outstanding?
Enlivex Therapeutics Ltd. - Ordinary Shares has 21M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.